Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Dermatol ; 34(1): 58-60, 1995 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7896491

RESUMO

BACKGROUND: Interferon is considered to be an important curative agent for dermatologic diseases. We report the follow-up experience of patients with basal cell or squamous cell carcinomas treated with human natural leukocyte interferon (HNLI). RESULTS: Among 52 patients with basal cell carcinoma (BCC) treated with HNLI more than 10 years ago, and among 58 treated more than 5 years ago, only 2 recurrences were observed. There were no recurrences in 75 patients who had a complete response to HNLI treatment, nor were there any in 20 patients with either a partial or complete response to r.IFM alpha 2c treatment. Of 52 patients with squamous cell carcinoma (SCC), 31 had been treated more than 10 years earlier, two recurrences of the disease at the site of the original lesion were observed. CONCLUSION: Interferon treatment makes it possible to achieve a persistent cure in patients with BCC and SCC in a high proportion of cases. The potential advantage of nonsurgical treatment are an enhancement of cosmetic results through the prevention of destruction of important anatomic structures.


Assuntos
Carcinoma Basocelular/prevenção & controle , Carcinoma de Células Escamosas/prevenção & controle , Interferon Tipo I/uso terapêutico , Interferon-alfa/uso terapêutico , Recidiva Local de Neoplasia/prevenção & controle , Neoplasias Cutâneas/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Basocelular/patologia , Carcinoma Basocelular/terapia , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/terapia , Neoplasias Faciais/patologia , Neoplasias Faciais/prevenção & controle , Neoplasias Faciais/terapia , Feminino , Seguimentos , Humanos , Interferon Tipo I/administração & dosagem , Interferon-alfa/administração & dosagem , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/cirurgia , Proteínas Recombinantes , Indução de Remissão , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA